🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Bioatla Inc (BCAB)

NASDAQ
Currency in USD
2.079
-0.142(-6.37%)
Real-time Data
BCAB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
2.0402.260
52 wk Range
1.1404.020
Prev. Close
2.22
Open
2.25
Day's Range
2.04-2.26
52 wk Range
1.14-4.02
Volume
866,758
Average Vol. (3m)
1,177,096
1-Year Change
34.55%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
BCAB Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
10.667
Upside
+413.083%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period
Show more

Bioatla Inc Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

InvestingPro Research for Bioatla Inc


Market Potential
Uncover BioAtla's strategic partnership pursuits and upcoming data presentations, potentially catalyzing investor interest and validating its technology platform
Financial Outlook
Analyze BioAtla's $61.7M cash position, providing runway for clinical programs amid no current revenue, with a $5 price target from JMP Securities
Pipeline Progress
Delve into BioAtla's key assets: Evalstotug, Ozuriftamab, and Mecbotamab, showing encouraging response rates across multiple solid tumor indications
Innovative Therapies
Explore BioAtla's Conditionally Active Biologics (CABs) and Antibody-Drug Conjugates (ADCs), poised to disrupt oncology with promising clinical results
Read full SWOT analysis

Compare BCAB to Peers and Sector

Metrics to compare
BCAB
Peers
Sector
Relationship
P/E Ratio
−1.0x−1.3x−0.6x
PEG Ratio
−0.06−0.040.00
Price / Book
3.2x1.1x2.6x
Price / LTM Sales
-3.6x3.3x
Upside (Analyst Target)
-304.7%45.3%
Fair Value Upside
Unlock21.6%6.1%Unlock

People Also Watch

1.710
OLPX
+5.56%
4.64
HPP
+0.87%
100.04
FOUR
+2.56%
339.78
GEV
+0.89%
329.97
MOH
-2.29%

FAQ

What Is the Bioatla (BCAB) Stock Price Today?

The Bioatla stock price today is 2.079

What Stock Exchange Does Bioatla Trade On?

Bioatla is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Bioatla?

The stock symbol for Bioatla is "BCAB."

What Is the Bioatla Market Cap?

As of today, Bioatla market cap is 100.54M.

What is Bioatla Earnings Per Share?

The Bioatla EPS is -2.18.

What Is the Next Bioatla Earnings Date?

Bioatla will release its next earnings report on Mar 20, 2025.

From a Technical Analysis Perspective, Is BCAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.